25TFM-NBOMe (also known as NBOMe-2C-TFM, 2C-TFM-NBOMe, and Cimbi-138) is a derivative of the phenethylamine hallucinogen 2C-TFM, discovered by Ralf Heim at the Free University of Berlin by 2000. It can be taken to produce psychedelic effects similar to 25I-NBOMe and 25D-NBOMe.
Interactions
Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A 5-HT1B 5-HT1D 1,817 5-HT1E 5-HT1F 5-HT2A 0.35–0.49 (Ki)0.96–2.0 ()80–92% () 5-HT2B 1.1 (Ki) () () 5-HT2C 2.7 (Ki) (rat)11.5 ()110% () 5-HT3 5-HT4 5-HT5A 8,128 5-HT6 23.4 5-HT7 5,974 α1A–α1D α2A–α2C β1–β3 D1–D5 H1–H4 M1–M5 I1 σ1, σ2 (Ki) () () (Ki) () () (Ki) () () Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:
25TFM-NBOMe acts as a potent partial agonist for the serotonin 5-HT2A receptor, though its relative potency is disputed, with some studies finding it to be of lower potency than 25I-NBOMe, while others show it to be of similar or higher potency, possibly because of differences in the assay used.
Chemistry Analogues Analogues of 25TFM-NBOMe include 2C-TFM, DOTFM, and TFMFly (DOTFM-FLY), among others.
History 25TFM-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin by 2000.
Society and culture Legal status Canada 25TFM-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.
United Kingdom
See also 25-NB (psychedelics)
References
External links 25TFM-NBOMe - Isomer Design